Replies to post #1696 on Phio Pharmaceuticals Corp (PHIO)

[pistol1p]

Pretty common, over the last year, that shorty comes out on the days when the company updates the clinical trial program.

I have come to expect it and look to add to my position. Nothing negative or surprising in the information released today. Over the past two weeks, RXII's volume has been increasing, and I have taken that as a positive moving forward.

I think that both the Hypertrophic Dermal Scars trial, and RXI-109 Treatment to Reduce the Formation of Keloids Following Keloidectomy trial will and have been positive.

I have held RXII for a few years and will continue to hold as these trials continue to show positive results.